Galenica AG · SIX:GALE
Galenica — Investor Presentation (August 2019)
46 slides from Galenica's investor presentation, August 2019
Slide 1: Galenica Group Investor Presentation
Galenica Group Investor Presentation August 2019
Slide 2: Agenda
Agenda 1 History 3 2 Galenica at a glance 6 3 Business Sectors 11 4 Financial track record 16 5 Business update H1 2019 18 6 Financial results H1 2019 26 7 Market update H1 2019 38 8 Regulatory projects update H1 2019 40 August 2019 © Galenica Group 2
Slide 3: Building the leading Swiss healthcare platform over 90 years
1 Building the leading Swiss healthcare platform over 90 years Creation of Foundation of Acquisition of Amavita uniform Acquisition of Galenica as a Merfen® and brand in Bahnhof wholesaler Vita-Merfen® Organic and Switzerland Apotheke acquisition-led expansion of Acquisition of Expansion of IPO of p
Slide 4: History of resilient growth and margin improvement
1 History of resilient growth and margin improvement Logistics, HealthCare Information & Retail1,4 Galenica 2008–18 CAGRs 2008-18 3.4% Retail market sales2 1.9% sales CAGR Galenica net sales 3.4% Galenica EBIT3 14.7% 2008-18 6 14.7% 3’141 3’165 6 6.0% EBIT CAGR3 2’915 3’009 2’661 2’766 2’826 2008-18
Slide 5: April 2017: Outstanding IPO of Galenica Santé
1 7 April 2017: Outstanding IPO of Galenica Santé Largest IPO in Europe in H1 2017 and first sizeable 100% subsidiary IPO since years Multiple oversubscription with pricing at the top end of the price range at CHF 39.00 HF 13% RoW 15% PB Broadly diversified 30% US 48.75m 12% 48.75m allocation
Slide 6: Galenica is the leading healthcare provider in Switzerland
2 Galenica is the leading healthcare provider in Switzerland 2018 net sales CHF3’165m 2018 EBIT1 CHF154m Health & Beauty Services Retail Products & Brands Market position2 #1 Consumer Health market position2 #1 Market position2 #1 2018 net sales 2018 EBIT 2018 net sales 2018 EBIT (pre eliminations o
Slide 7: Operating in a stable and attractive Swiss healthcare market
Operating in a stable and attractive Swiss healthcare market 2 with favourable long-term fundamentals Resilient, stable Swiss healthcare retail sector2 Pharmaceutical market in Switzerland (2018)1 CHF bn (based on ex-manufacturer price) 2018-22 CAGR 1.7%3 By value−CHF6.0bn By volume−187 million pack
Slide 8: Experienced management team with proven track record
2 Experienced management team with proven track record Jean-Claude Clémençon − CEO since IPO CEO − 30 years industry experience of which 24 years at Galenica Group − Joined Galenica Group in 1995 − Previously, Head of Retail Business Sector, Head of Logistics and HCI at Galenica Group, Head of Manuf
Slide 9: Galenica: The first choice for health, beauty and wellbeing
2 Our ambition and self-perception Galenica: The first choice for health, beauty and wellbeing. August 2019 © Galenica Group 9
Slide 10: Our Strategy - the power of Leverage
2 Our Strategy - the power of 3 drives sustained value creation Products & Brands − Leverage leading positions to promote − Develop and launch own and partner higher margin and exclusive products brands and products for pharmacies Leverage − Further expand and optimise retail 2017 2016 Retail networ
Slide 11: The largest pharmacy retailer in Switzerland
3 The largest pharmacy retailer in Switzerland Retail Network of chains (# of pharmacies as of 30 June 2019) Webshop Competitive positioning—#1 market position4 − Largest branded pharmacy network by By number of pharmacies5 Total # of pharmacies as of 2017 number of pharmacies in Switzerland 1’800
Slide 12: Ongoing pharmacy network consolidation and optimisation
3 Ongoing pharmacy network consolidation and optimisation Retail Proven track record of delivering synergies Widely spread pharmacy network covers every through streamlining of business processes and Region in Switzerland creating value through acquisitions and network optimisation Marketing IT
Slide 13: Diversified product portfolio for health, beauty and wellbeing
3 Diversified product portfolio for health, beauty and wellbeing Retail GaleniCare’s retail product offering in % of sales1 12% 37% 19% 52% 17% 11% 4% Beauty Nutrition, Personal OTC medicines Prescription medicines and Patient Care of which originals of which generics 1 Sales YTD December 2018, incl
Slide 14: Leading role in Consumer Health with broad and innovative product portfolio
Leading role in Consumer Health 3 with broad and innovative product portfolio Products & Brands Portfolio Competitive position: #1 Consumer Healthcare1 market position OTC Consumer Health ORAL PAIN & Skincare brands REMEDIES5 Market share2 (%) No. 1 33% market share2 5.7 5.3 5.3 TOPICAL PAIN Exclusi
Slide 15: Leader in pre-wholesale and wholesale distribution
Leader in pre-wholesale and wholesale distribution, supported 3 by an innovative healthcare information business Services Services Competitive positioning - #1 market position1 − Pre-wholesale outsourced storage and distribution Pre-wholesale market share % Wholesale market share % − Logistics servi
Slide 16: Long-term track record of sustainable growth and attractive cash generation
Long-term track record of sustainable growth and 4 attractive cash generation … Logistics, HealthCare Information & Retail1,4 Galenica 2008–18 CAGRs Retail market sales2 1.9% Galenica net sales 3.4% Net sales (CHFm) Galenica EBIT3 14.7% 3’009 3’141 7 3’165 7 Above market growth 2’766 2’826 2’915 2
Slide 17: Demonstrating strong performance in both segments
4 … demonstrating strong performance in both segments Health & Beauty Services Retail Health & Beauty Logistics and HCI Services 17.5% 3.5% 0.8% 2.2% Net sales (CHFm) 2’245 2’329 2’362 1 2’372 1 2’076 2’158 2’171 1’393 1’437 1’479 1 1’525 1 1’246 1’335 557 2008A … 2013A Health 2014A & Beauty 2015A 2
Slide 18: Guidance 2019 slightly increased
Based on the good 1st HY results: 5 Guidance 2019 slightly increased Increase of − net sales: + 2.2% − EBIT1): + 8.3% sustainable sales growth above market strong improvement of profitability progress in efficiency and synergy projects 1) adjusted: on a comparable basis, excluding the effects
Slide 19: All Business sectors contributed to the good results
Networked with all healthcare market players 5 All Business sectors contributed to the good results Products Patient / Customer & Brands Industry Retail Services August 2019 © Galenica Group 19
Slide 20: Highlights 1st HY 2019 Retail: Strong expansion activities
Highlights 1st HY 2019 5 Retail: Strong expansion activities + 8 additional own pharmacies network of total 508 POS new services more than 40,000 products Bichsel acquisition Curarex acquisition August 2019 © Galenica Group 20
Slide 21: Retail: our latest acquisition – The Bichsel Group
Highlights 1st HY 2019 5 Retail: our latest acquisition – The Bichsel Group Pharmacy store Magistral Prescriptions customised production Manufacture infusions, rinsing solutions Home Care August 2019 © Galenica Group 21
Slide 22: Products & Brands: Expansion of partnerships and portfolio
Highlights 1st HY 2019 5 Products & Brands: Expansion of partnerships and portfolio New own derma-cosmetic brand National advertising campaign Expansion of partnerships and product portfolio August 2019 © Galenica Group 22
Slide 23: Services: Pleasing progress with key strategic projects
Highlights 1st HY 2019 5 Services: Pleasing progress with key strategic projects Introduction new ERP system on track Modernisation logistic centre on track New products and services August 2019 © Galenica Group 23
Slide 24: Outlook 2019 Focus on our strategic axes
Outlook 2019 5 Focus on our 3 strategic axes Expansion − Further strengthening the three B2C channels − New services and products − New partnerships Innovation − Continue the positive momentum of the strategic projects ERP system Efficiency logistic centre Lausanne August 2019 © Galenica Group 2
Slide 25: Long-term outlook: From multi-channel to omni-channel
Long-term outlook 5 From multi-channel to omni-channel … multi-channel omni-channel August 2019 © Galenica Group 25
Slide 26: Galenica Group Sales growth above market
Galenica Group 6 Sales growth above market Net sales (in million CHF) +2.2% +4.3% +11.1% +1.3% H1 2019 H1 2018 August 2019 © Galenica Group 26
Slide 27: Retail Business sector: Important sales growth driven by expansion
Retail Business sector 6 Important sales growth driven by expansion Net sales (in million CHF) +4.3% 48.6% Elements of growth: Expansion1: +2.6% +1.3% +5.1% Organic2: +0.5% +1.3% -0.7% thereof impact of price reductions3: -1.6% -1.2% -1.9% Strong expansion of pharmacy network: 13 pharmacies added,
Slide 28: Products & Brands: Consolidation of leading position in Swiss Consumer Healthcare
Products & Brands Business sector - Consolidation of leading 6 position in the Swiss Consumer Healthcare market Net sales (in million CHF) +11.1% +3.0% International sales 53.0% Sales in the Swiss Market +13.6% Distribution of P&G brands Vicks® and Metamucil® and launch of Dermafora® with ~ 10% im
Slide 29: Services Business sector: Gain of market shares in the pharmacy market
Services Business sector 6 Gain of market shares in the pharmacy market Net sales (in million CHF) +1.3% 49.6% impact of price reductions1: -2.4% -1.9% -2.6% Pleasing growth of ~ 2.2% in the pharmacy wholesale market (portion ~ 65%) outweighs slight decline of ~ 0.8% in the physician wholesale mar
Slide 30: Results and profitability improved
Galenica Group 6 Results and profitability improved EBITDA (in million CHF) EBIT (in million CHF) +41.7% +18.1% 4.9% 4.5% 5.2% EBIT Margin (ROS) August 2019 © Galenica Group 30
Slide 31: EBITDA and EBIT adjustments
Galenica Group 6 EBITDA and EBIT adjustments1 EBITDA (in million CHF) EBIT (in million CHF) H1 H1 H1 H1 2019 2018 2019 2018 EBITDA 126.7 89.4 EBIT 82.8 70.1 Adjustment IAS 19 -0.3 +4.8 Adjustment IAS 19 -0.3 +4.8 Adjustment IFRS 16 -24.6 - Adjustment IFRS 16 -1.4 - EBITDA adjusted 101.8 94.2 EBIT ad
Slide 32: EBIT / EBIT margin adjusted
Galenica Group 6 Results and profitability improved EBIT / EBIT margin adjusted 1 (in million CHF / %) 5.1% +8.3% 4.8% 7.7% +11.0% 7.3% 1.9% +1.2% 1.9% August 2019 © Galenica Group H1 2019 H1 2018 1 Excluding effects of IAS 19 and IFRS 16, half-year report on pages 20 and 21 32
Slide 33: Stable financial and tax costs
Galenica Group 6 Stable financial and tax costs Financial result (in million CHF) Tax rate -1.1 -1.3 -1.9 1 -0.1 -1.3 -0.2 -1.5 -2.1 -2.7 2018 H1 2018 H1 2019 Financial result adjusted2 IAS 19 and IFRS 16 effects2 The Swiss Tax Reform has had no material impact on income taxes 1 Effective tax rate
Slide 34: Pleasing net profit evolution
Galenica Group 6 Pleasing net profit evolution Net profit (in million CHF) +15.0% One-off deferred tax effect Net profit adjusted1, excluding effects of IAS 19 +7.6% and IFRS 16, 2018 w/o one-off tax effect IAS 19 and for H1 2019 IFRS 16 and IAS 19 effects -0.1 1 Details of the adjustments in the ha
Slide 35: Investments in efficiency projects
Galenica Group 6 Investments in efficiency projects Investments in million CHF % of net sales 1.6% 1.4% 1.5% Cash conversion1 74% 77% 76% Investments in intangible assets Investments in tangible assets 1 Calculated as (EBITDA adjusted-CAPEX)/EBITDA adjusted, EBITDA adjusted excluding effects of IAS
Slide 36: Free cash flow impacted by working capital, investments and acquisitions
Galenica Group - Free cash flow impacted by working capital, 6 investments and acquisitions1 in million CHF H1 H1 2019 2018 Cash flow from operating activities 116.0 87.0 before working capital changes Payment of lease liabilities -23.4 - Cash flow from operating activities before 92.6 87.0 working
Slide 37: Strong balance sheet
Galenica Group 6 Strong balance sheet Net debt / Equity in million CHF Debt coverage 1 2.0x 2.0x 2.6x Debt coverage adjusted 2 1.5x 1.9x 2.0x 50%3 41%3 46%3 30%3 54%4 50%4 48%4 Net debt adjusted5 19%3 16%3 IFRS 16 effect on net debt Equity adjusted5 21%4 16%4 19%4 IAS 19 and IFRS 16 effect on equity
Slide 38: Swiss pharmaceutical market by channel YTD June 2019
Swiss pharmaceutical market by channel YTD June 2019 7 Modest growth marked by price reductions Value (ex-factory): CHF 2,984.9 million Volume (packs): CHF 93,2 million (CHF +26,8 million / +0.9%) (CHF -0.9 million / -0.9%) Hospitals Hospitals 753.6 million 8.3 million 8.9% +4.2% -4.3% 3.4% 25.3% Dr
Slide 39: Consumer healthcare market in the specialist trade YTD June 2019
Consumer healthcare market in the specialist trade YTD June 2019 7 Stable market development 3.3% OTC 11.9% +0.5% Personal 1’256 care +0.7% million 22.5% (+0.1%) Patient non-medication 62.2% care -2.7% products -0.4% Nutrition -0.8% Source: PharmaTrend for pharmacies and drugstores in Switzerland, s
Slide 40: Regulatory update: Positive signal from authorities
Regulatory update 8 Positive signal from authorities Reduction in drug 2018 prices 2019 2020 Decision by the Federal Council Category change of OTC products1) 2019 Distribution margin LOA IV LOA V LOA IV extended to the end of 2021 Generics prices Amendment of Health from 2021 … Insurance Ac
Slide 41: Price reductions 2017, 2018 and outlook 2019
Price reductions 2017, 2018 and outlook 2019 8 Annual savings per channel at public price and ex-factory in million CHF 2017 2018 Outlook 2019 Introduced in H1 2018 Introduced on 1.12.2018 Introduction planned for 1.12.2019 225 Hosp. 44.6 185 Hosp. 41.0 ~142 Physicians 64.8 122 Hosp. Physicians Hosp
Slide 42: Reclassification of OTC's
8 Reclassification of OTC’s Category A Category B Category C Category D Category E prescription without prescription pharmacy only pharmacy & drugstore sale in all shops repetition with a prescription with a prescription without prescription without prescription without prescribtion ~15% ~85% ~85% ~
Slide 43: Category change of OTC products
Category change of OTC products 8 Strengthening of the specialist retail trade Less than 10% of products will leave the specialist retail trade! DE CHF 13 million List D CHF 575 million CB CHF 30 million CD CHF 142 million Source: IQVIA, ex-factory, MAT 10/2018 August 2019 © Galenica Group 43
Slide 44: Swiss Pharmaceutical market – composition of drug prices
8 Swiss Pharmaceutical market – composition of drug prices Fixed margin elements help to offset price reductions Composition of the price of a prescription/ reimbursable drug: c.3/4 of the retail margin secured by fixed elements ~ 8 %(1) LOA – Retail ~ 8% Per prescription / line service fees FOPH de
Slide 45: Disclaimer
Disclaimer Disclaimer Galenica Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company’s or, as appropriate, the Company’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a n
Slide 46: Contact information Investor Relations Media
Galenica Group - Contact information Investor Relations Media Felix Burkhard Christina Hertig CFO Galenica Head Corporate Communication Tel.: +41 58 852 85 29 Tel.: +41 58 852 85 17 Mail: [email protected] Mail: [email protected] August 2019 © Galenica Group 46